Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Assembly Biosciences, Inc. - Common Stock (NQ:ASMB)

34.00 +1.27 (+3.88%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Assembly Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Moves Lower; Bank of America Profit Beats Expectations ↗
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling around 50 points on Tuesday. The Dow traded down 0.09% to 33,954.39 while the NASDAQ fell 0.37% to... 
Via Benzinga
Topics Stocks
News headline image
Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Surges 100 Points; Goldman Sachs Posts Upbeat Earnings ↗
U.S. stocks traded mostly higher midway through trading, with the Dow Jones falling gaining around 100 points on Tuesday. The Dow traded up 0.31% to 34,090.15 while the NASDAQ fell 0.05% to 13,560.52.... 
Via Benzinga
Topics Stocks
News headline image
Why Are Stocks Down Today? ↗
Stocks are down today, and investors wondering why are in the right place as we have all the details they need to know about on Tuesday! 
Via InvestorPlace
News headline image
Why Is Assembly Biosciences (ASMB) Stock Up 92% Today? ↗
Assembly Biosciences stock is taking off with heavy trading of ASMB shares after the company announced a new collaboration agreement! 
Via InvestorPlace
News headline image
Nasdaq Down Over 1%; US Retail Sales Top Expectations ↗
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 1% on Tuesday. Following the market opening Tuesday, the Dow traded down 0.11% to 33,947.98 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
News headline image
Hepatitis-Focused Assembly Biosciences Stock Trading Over 100% Higher: Here's Why ↗
Gilead Sciences Inc (NASDAQ: GILD) and Assembly Biosciences Inc (NASDAQ: ASMB) have entered into a 12-year partnership. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs ↗
Assembly Biosciences Inc (NASDAQ: ASMB) announced interim efficacy, safety, and pharmacokinetic (PK) results from a Phase 1b study of ABI-H3733 (3733) and a Phase 1a study of ABI-4334 (4334). 
Via Benzinga
News headline image
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation
From Assembly Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.